title: Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice.
abstract: Antisense-mediated exon skipping is a promising therapeutic approach for Duchenne muscular dystrophy. It aims to restore the dystrophin open reading frame by skipping exons with antisense oligonucleotides (AONs) to allow production of partly functional proteins. The approach is currently tested in phase 3 clinical trials, but dosing and maintenance regimens have not yet been well studied. This study compared pharmacokinetic and pharmacodynamic effects of different 2'-O-methyl phosphorothioate RNA AON dosing and maintenance regimens in the preclinical mdx mouse model. When comparing different dosing regimens over a period of 8 weeks, higher levels of AON, exon skipping, and protein were observed in muscle after low daily doses compared with large weekly doses. Secondly, after receiving a high loading dose (1,250 mg/kg) in the first week, mice treated with maintenance injections twice weekly for 8 weeks showed higher preservation of therapeutic effects than mice receiving less or no maintenance injections. In both cases, the regimen resulting in the highest AON and exon skipping levels in muscle also resulted in high AON levels in liver and kidneys. These studies underline the importance of balancing optimal AON efficacy and tolerable levels in non-target organs, which may be fine-tuned by further optimization of AON treatment regimens.
authors: Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands .
authors: Ingrid E C
authors: IE
authors: Verhaart
authors: Christa L
authors: CL
authors: Tanganyika-de Winter
authors: Tatyana G
authors: TG
authors: Karnaoukh
authors: Ingrid G M
authors: IG
authors: Kolfschoten
authors: Sjef J
authors: SJ
authors: de Kimpe
authors: Judith C T
authors: JC
authors: van Deutekom
authors: Annemieke
authors: A
authors: Aartsma-Rus
mesh_terms: D000818:Animals; D003402:Creatine Kinase / Q000097:blood; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D054796:Drug Dosage Calculations; D016189:Dystrophin / Q000819:agonists / Q000235:genetics* / Q000378:metabolism; D005091:Exons; D015316:Genetic Therapy; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D051379:Mice; D018101:Mice, Inbred mdx; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D020388:Muscular Dystrophy, Duchenne / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D016376:Oligonucleotides, Antisense / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology*; D054735:Phosphorothioate Oligonucleotides / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D016189:Dystrophin; D016376:Oligonucleotides, Antisense; D054735:Phosphorothioate Oligonucleotides; D003402:Creatine Kinase